Tag : HBV
Approximately 3.1 million people worldwide live with concomitant human immunodeficiency virus-1 (HIV-1) and hepatitis B virus (HBV) infection. Current guidelines recommend tenofovir alafenamide (TAF) or tenofovir disoproxil fumarate (TDF)-based antiretroviral therapies for most adults
Chronic hepatitis B virus (HBV) infection remains a significant global health challenge despite the availability of preventative vaccines. To address the unmet need for functional cure, immune-based treatments are gaining attention. VRON-0200, a therapeutic vaccine, has been developed to enhance and broaden T cell responses through the expression of HBV core and polymerase antigens fused with a genetically encoded checkpoint modifier (HSV-1 glycoprotein D). Interim data from an ongoing phase 1b trial was presented by Professor Wong, Lai-Hung Grace from The Chinese University of Hong Kong at the AASLD Annual Meeting 2024.
